OPT - Opthea Ltd (ASX) Stock Forum
Opthea Ltd (ASX:OPT) is an Australian biotechnology company that specializes in developing novel therapies for the treatment of eye diseases. The company's lead product candidate, OPT-302, is a potential treatment for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Opthea's innovative approach to treating eye diseases has garnered attention from Aussie stock traders and is a topic of discussion on investment forums.
